Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 26, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that John J. Kuch , senior vice president and chief financial
View HTML
Toggle Summary Xencor to Present Multiple Posters at the SITC Annual Meeting
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 27, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced three poster presentations at the 38th Annual Meeting of the
View HTML
Toggle Summary Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 19, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J.
View HTML
Toggle Summary Xencor Reports Second Quarter 2023 Financial Results
-- Management to Host Conference Call at 4:30 p.m. ET Today -- PASADENA, Calif. --(BUSINESS WIRE)--Aug. 3, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases,
View HTML
Toggle Summary Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 27, 2023-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2023 financial results after
View HTML
Toggle Summary Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
-- Engineered IL2-Fc Cytokine is Well-tolerated and Selectively Expands Regulatory T Cells -- PASADENA, Calif. --(BUSINESS WIRE)--May 30, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with
View HTML
Toggle Summary Xencor Reports First Quarter 2023 Financial Results
-- Management to Host Conference Call at 4:30 p.m. ET Today -- PASADENA, Calif. --(BUSINESS WIRE)--May 8, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases,
View HTML
Toggle Summary Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
PASADENA, Calif. --(BUSINESS WIRE)--May 1, 2023-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release first quarter 2023 financial results after
View HTML
Toggle Summary Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 26, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente , M.D., to Executive Vice
View HTML
Toggle Summary Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 17, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented new preclinical data generated from engineered CD28
View HTML